Experimental IPF Therapies: Cotrimoxazole
Cotrimoxazole (Trisulfa-FPI) is a combination of trimethoprim and sulfamethoxazole in fixed amounts (trimethoprim 80 mg and sulfamethoxazole 400 mg) used to treat bacterial, fungal and protozoal infections. It is developed and marketed worldwide with different brand names including Septra (GlaxoSmithKline plc) and Bactrim (Hoffmann-La Roche). Being a broad spectrum antibiotic, it also finds uses in other diseases where infections are secondary. Idiopathic Pulmonary Fibrosis (IPF) is one such disease where cotrimoxazole is being used as a therapeutic option.